Tenax Therapeutics (NASDAQ:TENX) Announces Earnings Results, Beats Expectations By $0.04 EPS

Tenax Therapeutics (NASDAQ:TENX) posted its earnings results on Thursday. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.04, FiscalAI reports.

Tenax Therapeutics Price Performance

NASDAQ:TENX traded down $0.18 during trading hours on Thursday, hitting $1.63. 1,959,451 shares of the company were exchanged, compared to its average volume of 2,122,420. The stock has a market capitalization of $60.99 million, a price-to-earnings ratio of -1.10 and a beta of 0.99. The company’s 50 day moving average price is $1.82 and its 200-day moving average price is $9.81. Tenax Therapeutics has a 52-week low of $1.31 and a 52-week high of $19.40.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. UBS Group downgraded Tenax Therapeutics to a “neutral” rating in a research report on Monday, August 31st. William Blair cut Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 10th. Leerink Partners set a $4.00 target price on Tenax Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen downgraded Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings lowered Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $14.00.

Insider Transactions at Tenax Therapeutics

In other news, Director Declan Doogan acquired 53,000 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were acquired at an average cost of $1.92 per share, with a total value of $101,760.00. Following the completion of the acquisition, the director owned 55,274 shares of the company’s stock, valued at approximately $106,126.08. This trade represents a 2,330.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Adar1 Capital Management, Llc acquired 331,979 shares of Tenax Therapeutics stock in a transaction dated Wednesday, October 21st. The stock was purchased at an average price of $1.66 per share, with a total value of $551,085.14. Following the completion of the purchase, the insider owned 7,447,000 shares of the company’s stock, valued at approximately $12,362,020. The trade was a 4.67% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 3,682,899 shares of company stock valued at $6,388,279. 10.81% of the stock is currently owned by insiders.

Key Stories Impacting Tenax Therapeutics

Here are the key news stories impacting Tenax Therapeutics this week:

• Positive Sentiment: Tenax said analyses of the LEVEL results identified a predictive-enrichment strategy that it is applying to an amended LEVEL-2 protocol. The FDA has also granted the company a Type C meeting, providing a path to discuss the program with regulators. Tenax third-quarter results and corporate update
• Positive Sentiment: Third-quarter loss was $0.31 per share, narrower than analysts’ $0.35-per-share estimate, a modest earnings beat. Tenax quarterly earnings report
• Negative Sentiment: Several law firms publicized a securities class action covering investors who bought TENX shares from November 13, 2023, through August 7, 2026. The suit alleges Tenax overstated TNX-103’s clinical prospects while raising funds before the LEVEL trial missed its primary endpoint; these are allegations, not established findings. The lead-plaintiff deadline is December 28, 2026. The litigation adds uncertainty and may weigh on investor sentiment. TENX shareholder lawsuit alert

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.